Previous 10 |
home / stock / flhlf / flhlf news
KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Viewing Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations PR Newswire NEW YORK , Oct. 18, ...
Filament Health to Webcast Live at VirtualInvestorConferences.com October 14th Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on its developments in natural psychedelics via VirtualInvestor...
Filament Health Announces DTC Eligibility and Up-List to the OTCQB Exchange Canada NewsWire VANCOUVER, BC , Oct. 12, 2021 /CNW/ - Filament Health Corp. (NEO: FH) (OTCQB: FLHLF) ("Filament" or the "Company"), an exclusively-natural psychedelic drug discovery ...
NEW YORK, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the September 16 th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live executive presentations ...
News, Short Squeeze, Breakout and More Instantly...
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - Negev Capital Fund One, L.P. (the " Acquiror "), a shareholder of Filament Health Corp. (" Filament "), announces that on June 12, 2024, it was issued 42,284,443 common shares of Filament (the " Common Shares ") from the conversion o...
FILAMENT HEALTH ANNOUNCES CLOSING OF WARRANT EXERCISE, NOTE CONVERSION AND CONCURRENT PRIVATE PLACEMENT OF COMMON SHARES Canada NewsWire VANCOUVER, BC , June 12, 2024 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (Cboe CA: FH) (FSE: 7QS) (" Filament " ...
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL FOR PEX010 IN THE TREATMENT OF METHAMPHETAMINE USE DISORDER Canada NewsWire Company study investigating PEX010, Filament's botanical psilocybin drug candidate, has been authorized by both FDA and Health Canada...